Literature DB >> 9252482

Intestinal growth-promoting properties of glucagon-like peptide-2 in mice.

C H Tsai1, M Hill, S L Asa, P L Brubaker, D J Drucker.   

Abstract

Glucagon-like peptide-2 (GLP-2) has been shown to promote intestinal epithelial proliferation. We studied crypt cell proliferation, enterocyte cell death, and feeding behavior in GLP-2-treated mice. GLP-2 had no effect on food consumption [7.7 +/- 0.3 vs. 8.0 +/- 0.4 g/day, saline (control) vs. GLP-2-treated mice, P = not significant]; however, GLP-2 increased the crypt cell proliferation rate (46.0 +/- 1 vs. 57 +/- 5%, control vs. GLP-2, P < 0.01) and decreased the enterocyte apoptotic rate (5.9 +/- 0.7 vs. 2.8 +/- 0.2% apoptotic cells, control vs. GLP-2, P < 0.05) in small bowel (SB) epithelium. GLP-2 induced a significant increase in SB weight (1.3- to 1.75-fold increase over control, P < 0.05 to P < 0.001) in mice 1-24 mo of age. Increased SB weight was maintained after daily administration of GLP-2 to mice for 12 wk, and cessation of GLP-2 administration in older mice led to regression of (increased) SB weight and mucosal height. These observations suggest that GLP-2 regulates both cell proliferation and apoptosis and promotes intestinal growth after both short- and long-term administration in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252482     DOI: 10.1152/ajpendo.1997.273.1.E77

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  65 in total

Review 1.  Hormonal regulation of physiological cell turnover and apoptosis.

Authors:  R D Medh; E B Thompson
Journal:  Cell Tissue Res       Date:  2000-07       Impact factor: 5.249

Review 2.  Gut adaptation and the glucagon-like peptides.

Authors:  D J Drucker
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

3.  Effects of intestinal resection on enterocyte apoptosis.

Authors:  J S Thompson; B Barent
Journal:  J Gastrointest Surg       Date:  1999 Nov-Dec       Impact factor: 3.452

Review 4.  Enhancing bowel adaptation in short bowel syndrome.

Authors:  Palle Bekker Jeppesen; Per Brobech Mortensen
Journal:  Curr Gastroenterol Rep       Date:  2002-08

5.  Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.

Authors:  Bharati Kochar; Millie D Long; Edward Shelton; Lorraine Young; Francis A Farraye; Vijay Yajnik; Hans Herfarth
Journal:  J Clin Gastroenterol       Date:  2017-07       Impact factor: 3.062

6.  Plasma GLP-2 levels and intestinal markers in the juvenile pig during intestinal adaptation: effects of different diet regimens.

Authors:  Monique C Paris; Peter J Fuller; Bendix Carstensen; Eva Nagy; Russell G Taylor; Magdy Sourial; Jens J Holst; Bolette Hartmann; Julie E Binesm
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

Review 7.  Gut hormones ghrelin, PYY, and GLP-1 in the regulation of energy balance [corrected] and metabolism.

Authors:  Diego Perez-Tilve; Ruben Nogueiras; Federico Mallo; Stephen C Benoit; Matthias Tschoep
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

8.  Glucagon-like peptide-2 (GLP-2) increases net amino acid utilization by the portal-drained viscera of ruminating calves.

Authors:  C C Taylor-Edwards; D G Burrin; N B Kristensen; J J Holst; K R McLeod; D L Harmon
Journal:  Animal       Date:  2012-05-09       Impact factor: 3.240

9.  Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2.

Authors:  D G Munroe; A K Gupta; F Kooshesh; T B Vyas; G Rizkalla; H Wang; L Demchyshyn; Z J Yang; R K Kamboj; H Chen; K McCallum; M Sumner-Smith; D J Drucker; A Crivici
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

10.  Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.

Authors:  J Thulesen; B Hartmann; K J Hare; H Kissow; C Ørskov; J J Holst; S S Poulsen
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.